SEARCH

SEARCH BY CITATION

References

  • Agid Y., Javoy-Agid F. & Ruberg M. (1987) Biochemistry of neurotransmitters in Parkinson's disease, in Movement Disorders 2 ( MarsdenC. D. and FahnS., eds), pp. 166230. Butterworths, London.
  • Bankiewicz K. S., Oldfield E. H., Chiueh C. C., Doppman J. L., Jacobowitz D. M. & Kopin I. J. (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39, 716.
  • Bezard E., Imbert C., Deloire X., Bioulac B. & Gross C. E. (1997) A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res. 766, 107112.DOI: 10.1016/s0006-8993(97)00531-3
  • Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C. & Yahr M. D. (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6–tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 106, 209210.
  • Davis G. C., Williams A. C., Markey S. P., Ebert M. H., Caine E. D., Reichert C. M. & Kopin I. J. (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogs. Psychiatry Res. 1, 249254.
  • Fahn S. & Przedborski S. (2000) Parkinsonism. In: Merritt's Neurology ( RowlandL. P., ed.), pp. 679693. Lippincott Williams & Wilkins, New York.
  • Forno L. S., Langston J. W., DeLanney L. E., Irwin I. & Ricaurte G. A. (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP- treated monkeys. Ann. Neurol. 20, 449455.
  • Forno L. S., DeLanney L. E., Irwin I. & Langston J. W. (1993) Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease: Neuropathologic considerations. Adv. Neurol. 60, 600608.
  • Fuller R. W., Hemrick Luecke S. K. & Perry K. W. (1988) Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Pharmacol. Exp. Ther. 247, 531535.
  • Giovanni A., Sieber B. A., Heikkila R. E. & Sonsalla P. K. (1991) Correlation between the neostriatal content of the 1-methyl-4- phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257, 691697.
  • Giovanni A., Sieber B.-A., Heikkila R. E. & Sonsalla P. K. (1994a) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J. Pharmacol. Exp. Ther. 270, 10001007.
  • Giovanni A., Sonsalla P. K. & Heikkila R. E. (1994b) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 270, 10081014.
  • Hamre K., Tharp R., Poon K., Xiong X. & Smeyne R. J. (1999) Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res. 828, 91103.DOI: 10.1016/s0006-8993(99)01273-1
  • Heikkila R. E., Manzino L., Cabbat F. S. & Duvoisin R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467469.
  • Heikkila R. E., Sieber B. A., Manzino L. & Sonsalla P. K. (1989) Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol. Chemic. Neuropathol. 10, 171183.
  • Jackson-Lewis V., Jakowec M., Burke R. E. & Przedborski S. (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4, 257269.
  • Javitch J. A., D'Amato R. J., Strittmatter S. M. & Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explain selective toxicity. Proc. Natl Acad. Sci. USA 82, 21732177.
  • Johannessen J. N., Adams J. D., Schuller H. M., Bacon J. P. & Markey S. P. (1985) 1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. Life Sci. 38, 743749.
  • Johannessen J. N., Chiueh C. C., Herkenham M. & Markey C. J. (1986) Relationship of the in vivo metabolism of MPTP to toxicity, in MPTP: a Neurotoxin Producing a Parkinsonian Syndrome ( MarkeyS. P. Castagnoli N. JrTrevor A. J. and KopinI. J., eds), pp. 173189. Academic Press, Orlando.
  • Kopin I. J. & Markey S. P. (1988) MPTP toxicity: implication for research in Parkinson's disease. Annu. Rev. Neurosci. 11, 8196.
  • Langston J. W. (1987) MPTP: the promise of a new neurotoxin, in Movement Disorders 2 ( MarsdenC. D. and FahnS., eds), pp. 7390. Butterworths, London.
  • Langston J. W. & Ballard P. (1983) Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 309, 310310.
  • Langston J. W. & Irwin I. (1986) MPTP: current concepts and controversies. Clin. Neuropharmacol. 9, 485507.
  • Langston J. W., Ballard P. & Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979980.
  • Langston J. W., Forno L. S., Tetrud J., Reeves A. G., Kaplan J. A. & Karluk D. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598605.
  • Markey S. P., Johannessen J. N., Chiueh C. C., Burns R. S. & Herkenham M. A. (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311, 464467.
  • Miller D. B., Ali S. F., O'Callaghan J. P. & Laws S. C. (1998) The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. NY Acad. Sci. 844, 153165.
  • Moratalla R., Quinn B., DeLanney L. E., Irwin I., Langston J. W. & Graybiel A. M. (1992) Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl Acad. Sci. USA 89, 38593863.
  • Moy L. Y., Albers D. S. & Sonsalla P. K. (1998) Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice. Brain Res. 790, 264269.DOI: 10.1016/s0006-8993(98)00069-9
  • Muthane U., Ramsay K. A., Jiang H., Jackson-Lewis V., Donaldson D., Fernando S., Ferreira M. & Przedborski S. (1994) Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp. Neurol. 126, 195204.DOI: 10.1006/exnr.1994.1058
  • Mytilineou C. & Cohen G. (1985) Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J. Neurochem. 45, 19511953.
  • Petzinger G. M. & Langston J. W. (1998) The MPTP-lesioned non-human primate: a model for Parkinson's disease, in Advances in Neurodegenerative Disorders. Parkinson's Disease ( MarwahJ. and TeiltelbaumH., eds), pp. 113148. Prominent Press, Scottsdale.
  • Pitts S. M., Markey S. P., Murphy D. L. & Weisz A. (1986) Recommended practices for the safe handling of MPTP, in MPTP: a Neurotoxin Producing a Parkinsonian Syndrome ( MarkeyS. P., CastagnoliN.Jr, TrevorA. J. and KopinI. J., eds), pp. 703716. Academic Press, Orlando.
  • Przedborski S., Jackson Lewis V., Popilskis S., Kostic V., Levivier M., Fahn S. & Cadet J. L. (1991) Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. Neurochirurgie. 37, 377382.
  • Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V. L. & Dawson T. M. (1996) Role of neuronal nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced dopaminergic neurotoxicity. Proc. Natl Acad. Sci. USA 93, 45654571.DOI: 10.1073/pnas.93.10.4565
  • Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S. & Almer G. (2000) The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci. 16, 135142.
  • Schneider J. S. & Roeltgen D. P. (1993) Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res. 615, 351354.
  • Schneider J. S., Tinker J. P., Van Velson M., Menzaghi F. & Lloyd G. K. (1999) Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J. Pharmacol. Exp. Ther. 290, 731739.
  • Seniuk N. A., Tatton W. G. & Greenwood C. E. (1990) Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 527, 720.
  • Snow B. J., Vingerhoets F. J., Langston J. W., Tetrud J. W., Sossi V. & Calne D. B. (2000) Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry 68, 313316.
  • Sonsalla P. K. & Heikkila R. E. (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129, 339345.
  • Staal R. G. & Sonsalla P. K. (2000) Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J. Pharmacol. Exp. Ther. 293, 336342.
  • Staal R. G., Hogan K. A., Liang C. L., German D. C. & Sonsalla P. K. (2000) In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 293, 329335.
  • Storey E., Hyman B. T., Jenkins B., Brouillet E., Miller J. M., Rosen B. R. & Beal M. F. (1992) 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 58, 19751978.
  • Tatton W. G. (1993) Selegiline can mediate neuronal rescue rather than neuronal protection. Mov. Disord. 8, S20S30.
  • Tetrud J. W., Langston J. W., Redmond D. E. Jr, Roth R. H., Sladek J. R. & Angel R. W. (1986) MPTP-induced tremor in human and non-human primates. Neurology 36, 308308.
  • Tipton K. F. & Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 11911206.
  • Vingerhoets F. J., Snow B. J., Tetrud J. W., Langston J. W., Schulzer M. & Calne D. B. (1994) Positron emission tomographic evidence for progression of human MPTP- induced dopaminergic lesions. Ann. Neurol. 36, 765770.
  • Yang S. C., Markey S. P., Bankiewicz K. S., London W. T. & Lunn G. (1988) Recommended safe practices for using the neurotoxin MPTP in animal experiments. Lab. Anim. Sci. 38, 563567.